{"brief_title": "A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis", "brief_summary": "This study will evaluate the effectiveness and safety of denosumab in treating women with Postmenopausal Osteoporosis.", "condition": "Osteoporosis", "intervention_type": "Drug", "intervention_name": "Denosumab", "description": "Denosumab 60 mg administered by subcutaneous injection", "arm_group_label": "Denosumab 60 mg Q6M", "other_name": "Prolia\u00ae", "criteria": "Inclusion Criteria: - Women who are 60 to 90 years of age may be eligible to participate - Bone mineral density (BMD) T-Score at hip or spine must be less than -2.5 Exclusion Criteria: - BMD T-Score at the hip or the spine of less than -4.0 - Patients with any severe or more than two moderate vertebral fractures on spinal x-ray at entry", "gender": "Female", "minimum_age": "60 Years", "maximum_age": "90 Years", "healthy_volunteers": "No", "id": "NCT00089791.xml"}